A Phase 3 interventional study of Icatibant and Placebo in Hereditary Angioedema, sponsored by Shire. Completed at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 2nd largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 3rd registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2009.
This study's enrollment of 98 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 8th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2009, is one of 23 in phase 3, and was the 10th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
This Phase III study consisted of two parts: A controlled phase and an open label extension (OLE) phase.
The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy and safety of icatibant compared with placebo for the first treated cutaneous and/or abdominal attack.
Patients with moderate to severe abdominal or cutaneous attacks were randomized to receive a single, blinded, subcutaneous injection of icatibant (30 mg) or placebo. After a protocol amendment, patients with mild to moderate laryngeal HAE attacks were also randomized to receive a single, blinded subcutaneous injection of icatibant (30 mg) or placebo in order to obtain blinded, controlled efficacy and safety data for this subset of subjects. Patients experiencing severe laryngeal attacks (post-amendment) or mild to severe laryngeal attacks (pre-amendment) were to receive open-label icatibant.
After treatment of the first attack in the controlled phase, patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the study was discontinued or the product was commercially available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet the following criteria to be enrolled in this study.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous injection of matching placebo
Drug: Placebo
Single subcutaneous injection of icatibant, 30 mg
Drug: Icatibant
Single subcutaneous injection of icatibant, 30 mg
Also known as: Firazyr
Single subcutaneous injection of matching placebo
Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient
Time to onset of symptom relief was calculated from study drug administration to onset of symptom relief, where onset of symptom relief was defined as the earliest of 3 consecutive measurements in which there was a 50% reduction from pretreatment in composite VAS score. Composite VAS score comprised 3 symptoms, including skin swelling, skin pain, and abdominal pain, for cutaneous and abdominal attacks and 5 symptoms, including skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change, for laryngeal attacks. Subjects who did not achieve symptom relief within the observation period were censored at the last observation time.
Time frame: Up to 120 hours post-dose
Time to Onset of Primary Symptom Relief
Time to primary symptom relief was calculated from the time of study drug administration to the onset of primary symptom relief, where onset of primary symptom relief was determined using the subject-assessed VAS score for a single primary symptom (determined by edema location) and defined as the earliest of 3 consecutive non-missing measurements in which a pre-specified reduction from the pretreatment value was met. Subjects who did not achieve primary symptom relief within the observation period were censored at the last observation time.
Time frame: Up to 120 hours post-dose
Time to Almost Complete Symptom Relief
Time to almost complete symptom relief was calculated from the time of study drug administration to almost complete symptom relief, where almost complete symptom relief was defined as the earliest of 3 consecutive non-missing measurements in which all VAS scores \<10 mm. Subjects who did not achieve almost complete symptom relief within the observation period were censored at the last observation time.
Time frame: Up to 120 Hours post treatment
Time to Subject-Assessed Initial Symptom Improvement
Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the subject as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
Time frame: Up to 120 hours post-dose
Time to Investigator-Assessed Initial Symptom Improvement
Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the investigator as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
Time frame: Up to 120 hours post-dose
| Milestone | Randomized-Icatibant (Blinded Treatment)-Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)-Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal |
|---|---|---|---|---|---|
| Started | 43 | 45 | 3 | 2 | 5 |
| Completed | 43 | 43 | 3 | 2 | 4 |
| Not completed | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Medical condition | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Milestone | Randomized-Icatibant (Blinded Treatment)-Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)-Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal |
|---|---|---|---|---|---|
| Started | 38 | 35 | 3 | 2 | 4 |
| Completed | 38 | 35 | 3 | 2 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Time to onset of symptom relief was calculated from study drug administration to onset of symptom relief, where onset of symptom relief was defined as the earliest of 3 consecutive measurements in which there was a 50% reduction from pretreatment in composite VAS score. Composite VAS score comprised 3 symptoms, including skin swelling, skin pain, and abdominal pain, for cutaneous and abdominal attacks and 5 symptoms, including skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change, for laryngeal attacks. Subjects who did not achieve symptom relief within the observation period were censored at the last observation time.
| Hours | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal |
|---|---|---|
| Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient | 2.0 (1.5 to 3.0) | 19.8 (6.1 to 26.3) |
Time to primary symptom relief was calculated from the time of study drug administration to the onset of primary symptom relief, where onset of primary symptom relief was determined using the subject-assessed VAS score for a single primary symptom (determined by edema location) and defined as the earliest of 3 consecutive non-missing measurements in which a pre-specified reduction from the pretreatment value was met. Subjects who did not achieve primary symptom relief within the observation period were censored at the last observation time.
| Hours | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal |
|---|---|---|
| Time to Onset of Primary Symptom Relief | 1.5 (1.0 to 2.0) | 18.5 (3.6 to 23.9) |
Time to almost complete symptom relief was calculated from the time of study drug administration to almost complete symptom relief, where almost complete symptom relief was defined as the earliest of 3 consecutive non-missing measurements in which all VAS scores \<10 mm. Subjects who did not achieve almost complete symptom relief within the observation period were censored at the last observation time.
| Hours | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal |
|---|---|---|
| Time to Almost Complete Symptom Relief | 8.0 (5.0 to 42.5) | 36.0 (29.0 to 50.9) |
Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the subject as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
| Hours | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal |
|---|---|---|
| Time to Subject-Assessed Initial Symptom Improvement | 0.8 (0.5 to 1.0) | 3.5 (1.9 to 5.4) |
Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the investigator as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
| Hours | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal |
|---|---|---|
| Time to Investigator-Assessed Initial Symptom Improvement | 0.8 (0.6 to 1.3) | 3.4 (2.6 to 6.0) |
Collected over Treatment emergent adverse events occurring within 16 days of study drug administration are included in the analysis. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Controlled Phase - Icatibant (Randomized) | — | 0/46 (0%) | 8/46 (17.4%) |
| Controlled Phase -Placebo (Randomized) | — | 5/46 (10.9%) | 12/46 (26.1%) |
| Controlled Phase - Icatibant (Open Label) | — | 0/6 (0%) | 0/6 (0%) |
| Open Label Extension - Icatibant (Open Label) | — | 7/82 (8.5%) | 23/82 (28%) |
| Event | Controlled Phase - Icatibant (Randomized) | Controlled Phase -Placebo (Randomized) | Controlled Phase - Icatibant (Open Label) | Open Label Extension - Icatibant (Open Label) |
|---|---|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 0/46 | 2/46 | 0/6 | 3/82 |
| Myocardial infarctionCardiac disorders | 0/46 | 1/46 | 0/6 | 0/82 |
| GastroenteritisInfections and infestations | 0/46 | 1/46 | 0/6 | 0/82 |
| TracheostomySurgical and medical procedures | 0/46 | 1/46 | 0/6 | 0/82 |
| ArrhythmiaCardiac disorders | 0/46 | 0/46 | 0/6 | 1/82 |
| Non-Cardiac Chest PainGeneral disorders | 0/46 | 0/46 | 0/6 | 1/82 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/46 | 0/46 | 0/6 | 1/82 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/46 | 0/46 | 0/6 | 1/82 |
| CholecystitisHepatobiliary disorders | 0/46 | 0/46 | 0/6 | 1/82 |
| Event | Controlled Phase - Icatibant (Randomized) | Controlled Phase -Placebo (Randomized) | Controlled Phase - Icatibant (Open Label) | Open Label Extension - Icatibant (Open Label) |
|---|---|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 5/46 | 9/46 | 0/6 | 11/82 |
| HeadacheNervous system disorders | 3/46 | 3/46 | 0/6 | 9/82 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/46 | 0/46 | 0/6 | 5/82 |
| Age, Continuous(years) | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)--Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal | Total |
|---|---|---|---|---|---|---|
| Mean | 36.1 ± 13.69 | 36.6 ± 11.18 | 40.3 ± 6.66 | 50.0 ± 22.63 | 41.6 ± 11.78 | 37.0 ± 12.46 |
| Sex: Female, Male(Participants) | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)--Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal | Total |
|---|---|---|---|---|---|---|
| Female | 27 | 29 | 2 | 1 | 2 | 61 |
| Male | 16 | 16 | 1 | 1 | 3 | 37 |
| Race/Ethnicity, Customized(Participants) | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)--Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 38 | 40 | 3 | 2 | 4 | 87 |
| Other | 2 | 5 | 0 | 0 | 1 | 8 |
| Region of Enrollment(Participants) | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)--Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal | Total |
|---|---|---|---|---|---|---|
| United States | 26 | 32 | 2 | 2 | 3 | 65 |
| Hungary | 3 | 1 | 0 | 0 | 0 | 4 |
| Canada | 1 | 0 | 0 | 0 | 0 | 1 |
| Ukraine | 0 | 1 | 0 | 0 | 0 | 1 |
| Romania | 3 | 1 | 1 | 0 | 0 | 5 |
| Australia | 2 | 3 | 0 | 0 | 0 | 5 |
| Russian Federation | 2 | 1 | 0 | 0 | 0 | 3 |
| South Africa | 2 | 1 | 0 | 0 | 1 | 4 |
| Israel | 4 | 5 | 0 | 0 | 1 | 10 |
| Weight (kg)(Participants) | Randomized-Icatibant (Blinded Treatment)--Non-laryngeal | Randomized-Placebo (Blinded Treatment)-Non-laryngeal | Randomized-Icatibant (Blinded Treatment)--Laryngeal | Randomized-Placebo (Blinded Treatment)-Laryngeal | Open-Label Icatibant-Severe Laryngeal | Total |
|---|---|---|---|---|---|---|
| <= 50 kg | 4 | 2 | 0 | 0 | 0 | 6 |
| >50-75 kg | 16 | 20 | 1 | 2 | 0 | 39 |
| >75-100 kg | 14 | 13 | 1 | 0 | 3 | 31 |
| >100 kg | 9 | 10 | 1 | 0 | 2 | 22 |
Ran from Jul 2009 to primary completion in Oct 2010, 14 months.
Results were first posted in Aug 2014, 3 years 10 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 14 months is below that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant